Borges, Á.H., Russell, M., Tait, D., Scriba, T.J., Nemes, E., Skallerup, P., van Brakel, E., Cabibbe, A.M., Cirillo, D.M., Leuvennink-Steyn, M. and Rutkowski, K.T., 2025. Immunogenicity, safety, and efficacy of the vaccine H56: IC31 in reducing the rate of tuberculosis disease recurrence in HIV-negative adults successfully treated for drug-susceptible pulmonary tuberculosis: a double-blind, randomised, placebo-controlled, phase 2b trial. The Lancet Infectious Diseases.
Immunogenicity, safety, and efficacy of the vaccine H56: IC31 in reducing the rate of tuberculosis disease recurrence in HIV-negative adults successfully treated for drug-susceptible pulmonary tuberculosis: a double-blind, randomised, placebo-controlled,
- Journal Articles
